Johnson & Johnson (JNJ) drew market attention after a pair of regulatory approvals expanded its healthcare portfolio across rare diseases and cancer treatments. The company secured U.S. Food and Drug Administration approval for Imaavy in the treatment of warm autoimmune hemolytic anemia, while European regulators approved the expanded use of Tecvayli in combination with daratumumab for patients with multiple myeloma. The two decisions span the company's immunology and oncology portfolios, reflecting Johnson & Johnson's focus on specialized medicines.

Johnson & Johnson shares traded at $273.44, gaining 0.64% after recovering from early market volatility.

FDA Expands Imaavy Approval for Rare Blood Disorder Treatment

Johnson & Johnson received approval from the U.S. Food and Drug Administration for the expanded use of Imaavy. The treatment now covers patients aged 12 years and older with warm autoimmune hemolytic anemia. The approval applies to patients who currently receive or previously received steroid treatment. Imaavy first won U.S. approval in 2025 as a therapy for generalized myasthenia gravis, another antibody-mediated autoimmune condition, and the new decision adds a second approved use.

Warm autoimmune hemolytic anemia is a rare condition in which the immune system destroys red blood cells. As a result, patients can experience severe anemia, fatigue, blood clots, and kidney complications. Treatment has historically centered on corticosteroids, leaving limited options for patients who do not respond adequately. Johnson & Johnson developed Imaavy to reduce harmful antibodies while maintaining broader immune functions. The treatment works by blocking the neonatal Fc receptor (FcRn), a protein that supports antibody activity in the bloodstream, and it is delivered through intravenous infusion every four weeks, with dosing based on patient weight.

The approval followed a study involving 115 adults during mid-to-late stage clinical development. The study showed stronger and more lasting improvements in hemoglobin levels among patients receiving Imaavy. After 24 weeks, more patients achieved sustained improvement compared with those receiving placebo treatment. Reported side effects included swelling, diarrhea, fever, infections, and infusion-related reactions.

European Approval Expands Tecvayli Cancer Treatment Use

Johnson & Johnson also received approval from the European Commission for an expanded application of Tecvayli. The decision allows Tecvayli, combined with daratumumab, to treat adults with relapsed or refractory multiple myeloma. Multiple myeloma is a cancer of plasma cells in the bone marrow, and although initial therapies often control the disease, many patients eventually relapse. The treatment provides another option for patients after previous therapies have failed.

Tecvayli is a bispecific antibody administered through a subcutaneous injection. It targets B-cell maturation antigen and CD3 to activate immune responses against cancer cells. Tecvayli was originally cleared as a standalone therapy for heavily pretreated patients, so the new approval moves the medicine to an earlier point in the treatment sequence. Daratumumab, marketed by the company as Darzalex, is itself a Johnson & Johnson medicine, meaning the pairing combines two therapies from the company's own oncology portfolio. Combining Tecvayli with daratumumab creates a treatment approach that targets multiple disease pathways.

The European approval relied on results from the Phase III MajesTEC-3 study, which formed the basis of the decision. The trial included patients who had received one to three previous lines of treatment, and it compared the Tecvayli combination against established treatment options that used daratumumab with other therapies.

The study reported improved progression-free survival and overall survival outcomes. The treatment combination reduced the risk of disease progression or death compared with standard therapies. In addition, more than 90% of patients without progression at six months remained stable after three years.

Johnson & Johnson Strengthens Pharmaceutical Growth Strategy

Johnson & Johnson continues to expand its pharmaceutical business, organized under its Innovative Medicine segment, through new approvals and treatment development. The company has focused on immunology, oncology, and rare disease medicines, and these areas remain important parts of its healthcare growth strategy.

In January 2026, Johnson & Johnson reported fourth-quarter 2025 sales of $24.56 billion, a 9.1% increase compared with the previous period. Net earnings also increased 49.1% to $5.11 billion during the quarter.

The latest regulatory decisions strengthen Johnson & Johnson's position in specialized healthcare markets and advance its global healthcare strategy through key regulatory wins. Imaavy expands the company's immunology portfolio through rare disease treatment, while Tecvayli's wider European use supports its presence in cancer care.